Business Description
Chiome Bioscience Inc
ISIN : JP3205350006
Total Employee Number:
65Description
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 20.33 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 9.8 | |||||
Beneish M-Score | -2.22 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.2 | |||||
3-Year EBITDA Growth Rate | 20.1 | |||||
3-Year EPS without NRI Growth Rate | 19.9 | |||||
3-Year FCF Growth Rate | 19 | |||||
3-Year Book Growth Rate | -23.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 86.43 | |||||
9-Day RSI | 81.16 | |||||
14-Day RSI | 72.54 | |||||
3-1 Month Momentum % | -19.1 | |||||
6-1 Month Momentum % | -37.39 | |||||
12-1 Month Momentum % | -48.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.07 | |||||
Quick Ratio | 5.82 | |||||
Cash Ratio | 4.81 | |||||
Days Inventory | 81.19 | |||||
Days Sales Outstanding | 28.7 | |||||
Days Payable | 59.48 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.2 | |||||
Shareholder Yield % | 2.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 61 | |||||
Operating Margin % | -149.99 | |||||
Net Margin % | -150.49 | |||||
EBITDA Margin % | -148.27 | |||||
FCF Margin % | -158.67 | |||||
OCF Margin % | -152.16 | |||||
ROE % | -68.38 | |||||
ROA % | -52.5 | |||||
ROIC % | -225.11 | |||||
3-Year ROIIC % | 497.74 | |||||
ROC (Joel Greenblatt) % | -301.94 | |||||
ROCE % | -63.74 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 9.49 | |||||
PB Ratio | 4.23 | |||||
Price-to-Tangible-Book | 4.23 | |||||
EV-to-EBIT | -5.98 | |||||
EV-to-EBITDA | -6.04 | |||||
EV-to-Revenue | 8.96 | |||||
EV-to-FCF | -5.65 | |||||
Price-to-GF-Value | 0.95 | |||||
Price-to-Median-PS-Value | 0.51 | |||||
| Price-to-Net-Current-Asset-Value | 4.76 | |||||
| Price-to-Net-Cash | 6.43 | |||||
Earnings Yield (Greenblatt) % | -16.72 | |||||
FCF Yield % | -14.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chiome Bioscience Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 615.153 | ||
| EPS (TTM) (円) | -13.12 | ||
| Beta | 0.3122 | ||
| 3-Year Sharpe Ratio | -0.16 | ||
| 3-Year Sortino Ratio | -0.33 | ||
| Volatility % | 23.09 | ||
| 14-Day RSI | 72.54 | ||
| 14-Day ATR (円) | 3.725025 | ||
| 20-Day SMA (円) | 73.95 | ||
| 12-1 Month Momentum % | -48.57 | ||
| 52-Week Range (円) | 65 - 143 | ||
| Shares Outstanding (Mil) | 81.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chiome Bioscience Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chiome Bioscience Inc Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| 2:1 Stock Split | 2014-03-27 | 2,940.00 (-14.78%) | ||
| 2:1 Stock Split | 2013-06-26 | 2,240.00 (-3.03%) | ||
| 2:1 Stock Split | 2012-03-28 | 261.25 (+1.95%) |
Show
Entries
Chiome Bioscience Inc Frequently Asked Questions
What is Chiome Bioscience Inc(TSE:4583)'s stock price today?
The current price of TSE:4583 is 円84.00. The 52 week high of TSE:4583 is 円143.00 and 52 week low is 円65.00.
When is next earnings date of Chiome Bioscience Inc(TSE:4583)?
The next earnings date of Chiome Bioscience Inc(TSE:4583) is .
Does Chiome Bioscience Inc(TSE:4583) pay dividends? If so, how much?
Chiome Bioscience Inc(TSE:4583) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Chiome Bioscience Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers